LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors

Learn more about:
Related Clinical Trial
Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma FLUOPANC-trial – Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers Minimally Invasive Pancreatoduodenectomy for Distal Cholangiocarcinoma QoL After Liver Surgery CH-EUS in Diagnosis of Inoperable Bile Duct Tumors Treatment of ARB202 Advanced Gastrointestinal Cancer Patients Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Molecular Epidemiology of Biliary Tree Cancers Prognostic Factors in Periampullary Tumors and Cysts RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor HLA Typing and Tumor Neoantigen Identification for a Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor Deep Liver Phenotyping and Immunology Study A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry. Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone Crossover Relative Bioavailability and Dose Escalation Study of TT-00420 Tablet in Patients With Advanced Solid Tumors Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors

Official Title

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors

Brief Summary

      A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor
      Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with
      Metastatic Solid Tumors

Detailed Description

      This is an open-label, uncontrolled, multicenter Phase 1/2 study with a dose escalation phase
      (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed/refractory
      metastatic solid tumors.

      Part 1: Dose Escalation Phase A dose-finding study will be conducted using a continuous
      reassessment method (CRM) to establish dose-limiting toxicities (DLTs) and the recommended
      Phase 2 dose (RP2D).

      Part 2: Cohort Expansion Phase The second part of the protocol will adopt a Simon's two-stage
      optimal design. The Sponsor plans expansion cohorts for specific solid tumors, eg, pancreatic
      cancer, cholangiocarcinoma and/or potentially other solid tumor types based on results from
      part 1.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]

Secondary Outcome

 Part 1 and 2: Pharmacokinetic (PK) profile of LYT-200: Maximum Plasma Concentration [Cmax]


Metastatic Cancer



Study Arms / Comparison Groups

 Part 1 dose escalation
Description:  LYT-200 in metastatic solid tumors


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 15, 2020

Completion Date

December 2022

Primary Completion Date

December 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Part 1 and Part 2

               1. Written Informed Consent (mentally competent patient, able to understand and
                  willing to sign the informed consent form)

               2. Age ≥ 18 years, male or non-pregnant female

               3. Histologically confirmed unresectable metastatic cancer (adenocarcinomas and
                  squamous cell carcinomas allowed). Patients with resectable disease are excluded

               4. Able to comply with the study protocol, as per Investigator's judgment

               5. Life expectancy > 3 months according to Investigator's judgement

               6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

               7. Coronavirus SARS-CoV-2 (COVID-19) negative patients.

               8. Patient able and willing to undergo pre- and on/post-treatment biopsies.
                  According to the Investigator's judgement, the planned biopsies should not expose
                  the patient to substantially increased risk of complications. Every effort will
                  be made that the same lesion is biopsied on repeat biopsies. If the patient is
                  eligible according to all other criteria but declines to consent to a biopsy or
                  there are other medical reasons precluding biopsy, this will be discussed with
                  the sponsor.

               9. Measurable disease, according to Response Evaluation Criteria in Solid Tumors
                  (RECIST) v1.1. Note that lesions intended to be biopsied should not be target

              10. Adequate hematologic and end organ function, defined by the following laboratory
                  results obtained prior to first dose of study drug treatment, provided no
                  anti-cancer treatment was administered within the last 7 days:

                    1. neutrophil count ≥ 1 x 109/L

                    2. platelet count ≥ 100 x 109/L; for hepatocellular carcinoma (HCC) in Part 1 ≥
                       50 x 109/L

                    3. hemoglobin ≥ 9.0 g/dL without transfusion in the previous week

                    4. creatinine ≤ 1.5 x upper limit of normal (ULN)

                    5. aspartate aminotransferase AST (SGOT) ≤ 3 x ULN (≤ 5 x ULN when HCC or
                       hepatic metastases are present)

                    6. alanine aminotransferase (ALT [SGPT]) ≤ 3 x ULN (≤ 5 x ULN when HCC or
                       hepatic metastases present)

                    7. bilirubin ≤ 1.5 x ULN (patients with known Gilbert's disease may have a
                       bilirubin ≤ 3.0 x ULN)

                    8. albumin ≥ 3.0 g/dL

                    9. international normalized ratio (INR) and partial thromboplastin time (PTT) ≤
                       1.5 x ULN

                   10. amylase and lipase ≤ 1.5 x ULN

              11. No evidence of active infection or infections requiring parenteral antibiotics,
                  and no serious infection within 4 weeks before study start.

              12. Women of child-bearing potential must have a negative pregnancy test within 72 h
                  prior to start of treatment. For women of childbearing potential: agreement to
                  remain abstinent (refrain from heterosexual intercourse) or to use contraceptive
                  methods that result in a failure rate of < 1% per year during the treatment
                  period and for at least 180 days after the last study treatment.

                  A woman is of childbearing potential if she is post-menarche, has not reached a
                  postmenopausal state (≥ 12 continuous months of amenorrhea with no identified
                  cause other than menopause), and has not undergone surgical sterilization
                  (removal of ovaries and/or uterus).

                  Examples of contraceptive methods with a failure rate of < 1% per year include
                  bilateral tubal ligation, male sterilization, hormonal contraceptives that
                  inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine
                  devices. The reliability of sexual abstinence should be evaluated in relation to
                  the duration of the clinical trial and the preferred and usual lifestyle of the
                  patient. Periodic abstinence (eg, calendar, ovulation, symptom-thermal, or post
                  ovulation methods) and withdrawal are not acceptable methods of contraception.
                  Fertile men must practice effective contraceptive methods during the study,
                  unless documentation of infertility exists.

              13. Four (4) weeks or 5 half-lives (whichever is shorter) since the last dose of
                  anti-cancer therapy before the first LYT 200 administration

              14. Continuation of bisphosphonate treatment (eg, zoledronic acid) or denosumab for
                  bone metastases, which have been stable for at least 6 months before C1D1, is

              15. Biliary or gastric outlet obstruction allowed, provided it is effectively drained
                  by endoscopic, operative, or interventional means

              16. Pancreatic, biliary, or enteric fistulae allowed, provided they are controlled
                  with an appropriate non-infected and patent drain (if any drains or stents are in
                  situ, patency needs to be confirmed before study start)

                  Additionally, for Part 1 only:

              17. Patients:

                    1. for whom there are no available standard of care options or

                    2. who are not eligible for available and indicated standard of care therapy.

                  Additionally, for Part 2 only:

              18. PDAC expansion cohort: 1st line metastatic patients who are either
                  gemcitabine-containing regimen naïve or at least 3 months out of having been
                  treated using a gemcitabine-containing regimen previously in a neoadjuvant or
                  adjuvant/locally advanced setting

              19. CRC and CCA expansion cohorts - patients who have received at least one prior
                  line of therapy in the metastatic setting

        Exclusion Criteria

          1. Patient unwilling or unable to follow protocol requirements

          2. Patient diagnosed with metastatic cancer of an unknown primary

          3. Prior or current illicit drug addiction (medical and recreational
             marijuana/cannabidiol [CBD]/ tetrahydrocannabinol [THC] would not be considered

          4. Clinically significant, active uncontrolled bleeding, and any patients with a bleeding
             diathesis (eg, active peptic ulcer disease). Prophylactic or therapeutic use of
             anticoagulants is allowed.

          5. Pregnant and/or lactating females

          6. Receiving any other investigational agents or participating in any other clinical
             trial involving another investigational agent for treatment of solid tumors within 4
             weeks or 5 half-lives of the administered drug (whichever is shorter) prior to Cycle
             1, Day 1 of the study, or other investigational therapy or major surgery within 4
             weeks of the date of consent, or planned surgery within 4 weeks of envisaged study
             start (this includes dental surgery).

          7. Radiation therapy within 4 weeks of the first dose of study drug, except for
             palliative radiotherapy to a limited field, such as for the treatment of bone pain or
             a focally painful tumor mass, and which does not jeopardize required measurable
             lesions for response assessment (RECIST v1.1).

          8. Patients with fungating tumor masses

          9. Patients with locally advanced PDAC without distant organ metastatic deposits

         10. Grade 4 immune-mediated toxicities with a prior checkpoint inhibitor. Grade 2 or Grade
             3 pneumonitis or any other Grade 3 checkpoint inhibitor-related toxicity that led to
             immunotherapy treatment discontinuation. Low-grade (< Grade 3) toxicities, such as
             neuropathy from prior treatments, manageable electrolyte abnormalities and
             lymphopenia, alopecia and vitiligo are allowed.

         11. History of second malignancy, except those treated with curative intent more than five
             years previously without relapse or low likelihood of recurrence (for example,
             non-melanotic skin cancer, cervical carcinoma in situ, early (or localized) prostate
             cancer, or superficial bladder cancer)

         12. Active brain or leptomeningeal metastases. Patients with brain metastases are eligible
             provided they have shown clinically and radiographically stable disease for at least 4
             weeks after definitive therapy and have not used steroids (> 10 mg/day of prednisone
             or equivalent) for at least 4 weeks prior to the first dose of study drug

         13. Evidence of severe or uncontrolled systemic diseases, congestive heart failure > New
             York Heart Association (NYHA) class 2, myocardial infarction (MI) within 6 months, or
             laboratory finding that in the view of the Investigator makes it undesirable for the
             patient to participate in the trial

         14. Any medical condition that the Investigator considers significant to compromise the
             safety of the patient or that impairs the interpretation of LYT 200 toxicity

         15. Serious non-healing wound, active ulcer, or untreated bone fracture

         16. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures. For the purposes of this study, "recurrent" is defined as greater
             than or equal to 3 drains in the last 30 days.

         17. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

         18. Significant vascular disease (eg, aortic aneurysm requiring surgical repair or recent
             arterial thrombosis) within 6 months of Cycle 1, Day 1

         19. History of pulmonary embolism, stroke or transient ischemic attack within 3 months
             prior to Cycle 1, Day 1

         20. History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             Cycle 1, Day 1

         21. Active auto-immune disorder (except type I/II diabetes, hypothyroidism requiring only
             hormone replacement, vitiligo, psoriasis, or alopecia areata)

         22. Requires systemic immunosuppressive treatment, including, but not limited to
             cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis
             factor (anti-TNF) agents. Patients who have received or are receiving acute, low dose
             systemic immunosuppressant medications (eg, ≤ 10 mg/day of prednisone or equivalent)
             may be enrolled. Replacement therapy (eg, thyroxine, insulin, physiologic
             corticosteroid replacement therapy [eg, ≤ 10 mg/day of prednisone equivalent] for
             adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
             The use of inhaled corticosteroids and mineralocorticoids (eg, fludrocortisone),
             topical steroids, intranasal steroids, intra-articular, and ophthalmic steroids is

         23. Severe tumor-related pain (Grade 3, Common Terminology Criteria for Adverse Events
             [CTCAE] v.5.0) unresponsive to broad analgesic interventions (oral and/or patches)

         24. Hypercalcemia(defined as greater than or equal to Grade 3, per CTCAE v 5.0)despite use
             of bisphosphonates

         25. Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk of treatment

         26. Received organ transplant(s)

         27. Patients undergoing dialysis

         28. For patients enrolled into nivolumab combination cohorts, no prior exposure to any
             anti-PD-1 or anti-PD-L1 agent in any prior lines of therapy. Additionally, patients
             diagnosed as dMMR/MSI-H are excluded.

         29. For Part 1, hormonal androgen deprivation therapy is allowed to continue for patients
             with metastatic castration-resistant prostate cancer.

         30. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for
             HCC < 6 weeks prior trial entry

         31. Hepatic encephalopathy or severe liver adenoma

         32. Child-Pugh score ≥ 7




18 Years - N/A

Accepts Healthy Volunteers



Aleksandra Filipovic, MD, Ph.D., 617-982-2550, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor


Study Sponsor

Aleksandra Filipovic, MD, Ph.D., Study Director, PureTech Health

Verification Date

November 2021